Skip to main
MYGN
MYGN logo

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 30 analyst ratings
Hold
Strong Buy 20%
Buy 13%
Hold 47%
Sell 20%
Strong Sell 0%

Bulls say

Myriad Genetics Inc has demonstrated robust growth within its Pharmacogenomics segment, reporting a 14% year-over-year increase in 2024, with GeneSight specifically achieving a 23% growth rate. Additionally, the company's prenatal testing services, including Prequel and Foresight tests, have experienced a combined growth rate of 12% year-over-year in the fourth quarter of 2024, and 17% growth for the full fiscal year 2024. With anticipated new product launches, particularly an expansion of hereditary cancer screening in the second half of 2025 and a promising outlook for continued growth in prenatal testing, Myriad Genetics is well-positioned to capitalize on market opportunities and sustain its momentum above historical growth rates.

Bears say

Myriad Genetics has faced significant setbacks that could adversely affect its financial outlook, notably the loss of reimbursement from a private payer for its GeneSight product and a change in NCCN guideline language, which may result in reduced near-term revenues. The FY25 revenue guidance of $840M-$860M falls short of analyst consensus estimates, raising concerns about the company's ability to sustain organic growth amidst competitive pressures and regulatory risks. Furthermore, ongoing challenges in relationships with payors, potential product development failures, and anticipated price erosion pose considerable risks to the company's operating performance and overall market position.

Myriad Genetics (MYGN) has been analyzed by 30 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 13% recommend Buy, 47% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 30 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.